PALISADE BIO, INC. Proceeds from Maturities, Prepayments and Calls of Short-term Investments
PALISADE BIO, INC. (PALI) reported Proceeds from Maturities, Prepayments and Calls of Short-term Investments of $5.00 million for the 12-month period ending 2018-12-31, per its 10-K filed 2020-03-27.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments · last filed 2020-03-27
- PALISADE BIO, INC. proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2018-12-31 was $0.00.
- PALISADE BIO, INC. proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2018-09-30 was $0.00.
- PALISADE BIO, INC. proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2018-06-30 was $0.00.
- PALISADE BIO, INC. proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2018-03-31 was $5.00M.
- PALISADE BIO, INC. proceeds from maturities, prepayments and calls of short-term investments for fiscal 2018 was $5.00M, a 0.00% change from fiscal 2017.
- PALISADE BIO, INC. proceeds from maturities, prepayments and calls of short-term investments for fiscal 2017 was $5.00M, a 33.49% decline from fiscal 2016.
- PALISADE BIO, INC. proceeds from maturities, prepayments and calls of short-term investments for fiscal 2016 was $7.52M, a 49.91% decline from fiscal 2015.
- PALISADE BIO, INC. proceeds from maturities, prepayments and calls of short-term investments for fiscal 2015 was $15.01M, a 50.07% increase from fiscal 2014.
| Period end | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 3 month | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 6 month | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 9 month | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 12 month |
|---|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | $0.00 derived: sum of 2 quarters · filed 2020-03-27 | $0.00 derived: sum of 3 quarters · filed 2020-03-27 | $5.00M 10-K · filed 2020-03-27 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $0.00 derived: sum of 2 quarters · filed 2019-11-14 | $5.00M 10-Q · filed 2019-11-14 | $5.00M derived: sum of 4 quarters · filed 2019-11-14 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $5.00M 10-Q · filed 2019-08-14 | $5.00M derived: sum of 3 quarters · filed 2019-08-14 | $5.00M derived: sum of 4 quarters · filed 2019-08-14 |
| 2018-03-31 | $5.00M 10-Q · filed 2019-05-14 | $5.00M derived: sum of 2 quarters · filed 2019-05-14 | $5.00M derived: sum of 3 quarters · filed 2019-05-14 | |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-22 | $0.00 derived: sum of 2 quarters · filed 2019-03-22 | $5.00M 10-K · filed 2019-03-22 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $5.00M 10-Q · filed 2018-11-14 | ||
| 2017-06-30 | $5.00M 10-Q · filed 2018-08-13 | |||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | $0.00 derived: sum of 2 quarters · filed 2018-04-02 | $0.00 derived: sum of 3 quarters · filed 2018-04-02 | $7.52M 10-K · filed 2018-04-02 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $0.00 derived: sum of 2 quarters · filed 2017-11-08 | $7.52M 10-Q · filed 2017-11-08 | $7.52M derived: sum of 4 quarters · filed 2017-11-08 |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $7.52M 10-Q · filed 2017-08-08 | $7.52M derived: sum of 3 quarters · filed 2017-08-08 | $7.52M derived: sum of 4 quarters · filed 2017-08-08 |
| 2016-03-31 | $7.52M 10-Q · filed 2017-05-10 | $7.52M derived: sum of 2 quarters · filed 2017-05-10 | $7.52M derived: sum of 3 quarters · filed 2017-05-10 | $7.52M derived: sum of 4 quarters · filed 2017-05-10 |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-23 | $0.00 derived: sum of 2 quarters · filed 2017-03-23 | $0.00 derived: sum of 3 quarters · filed 2017-03-23 | $15.01M 10-K · filed 2017-03-23 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-08 | $0.00 derived: sum of 2 quarters · filed 2016-11-08 | $15.01M 10-Q · filed 2016-11-08 | $15.01M derived: sum of 4 quarters · filed 2016-11-08 |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11 | $15.01M 10-Q · filed 2016-08-11 | $15.01M derived: sum of 3 quarters · filed 2016-08-11 | $25.01M derived: sum of 4 quarters · filed 2016-08-11 |
| 2015-03-31 | $15.01M 10-Q · filed 2016-05-09 | $15.01M derived: sum of 2 quarters · filed 2016-05-09 | $25.01M derived: sum of 3 quarters · filed 2016-05-09 | $25.01M derived: sum of 4 quarters · filed 2016-05-09 |
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | $10.00M derived: sum of 2 quarters · filed 2016-03-14 | $10.00M derived: sum of 3 quarters · filed 2016-03-14 | $10.00M 10-K · filed 2016-03-14 |
| 2014-09-30 | $10.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $10.00M derived: sum of 2 quarters · filed 2015-11-09 | $10.00M 10-Q · filed 2015-11-09 | |
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $0.00 10-Q · filed 2015-08-10 | ||
| 2014-03-31 | $0.00 10-Q · filed 2015-05-08 | |||
| 2013-12-31 | $0.00 10-K · filed 2016-03-14 | |||
| 2012-12-31 | $0.00 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |